nktr-255
Recombinant proteinexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 7, 2019 (NCT04136756)
Timeline
Indications
Studied for
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2/Phase 3
- Lymphoma, Non-Hodgkin · Phase 2/Phase 3
- Multiple Myeloma · Phase 1
- Rectal Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Interleukin-15AGONIST
IL15 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05632809 | Phase 2 | Apr 30, 2023 | Nektar Therapeutics, University of Texas at Houston |
| NCT05664217 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2022 | Nektar Therapeutics |
| NCT05359211 | Phase 1 | Dec 28, 2022 | Nektar Therapeutics, University of Washington |
| NCT05327530 | Phase 2 | Aug 17, 2022 | Merck, Merck KGaA, Merck Serono |
| NCT04616196 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2020 | Nektar Therapeutics |
| NCT04136756 | Phase 1 | Oct 7, 2019 | Nektar Therapeutics |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nektar Therapeutics | For profit | 5 | 3 | 3 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2022 |
| Merck Serono | For profit | 1 | 1 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2022 |
6 organizations
Page 1 / 1